Use of angiotensin-converting enzyme inhibitors or receptor blockers is associated with reduced mortality in patients with post-acute kidney injury: meta-analysis

H Shi; Q Peng; X-L Zhou; S-P Zhu; S-Y Sun

doi:10.26355/eurrev_202108_26447

Use of angiotensin-converting enzyme inhibitors or receptor blockers is associated with reduced mortality in patients with post-acute kidney injury: meta-analysis

Eur Rev Med Pharmacol Sci. 2021 Aug;25(15):4900-4908. doi: 10.26355/eurrev_202108_26447.

Authors

H Shi¹, Q Peng, X-L Zhou, S-P Zhu, S-Y Sun

Affiliation

¹ Department of Traditional Chinese Medicine, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong Province, China. shengyunsun2020@163.com.

PMID: 34355362
DOI: 10.26355/eurrev_202108_26447

Abstract

Objective: To investigate the association between the use of ACEis or ARBs and outcomes in patients recovering from AKI.

Materials and methods: We searched PubMed, MEDLINE, Cochrane Database, Web of Science and Embase databases from inception to May 2021 and performed a systematic review and meta-analysis using the "meta" package in R 4.0.3.

Results: Five cohort studies, published from 2018 to 2021 with 153174 participants and approximately 39081 mortalities, were included in our meta-analysis. The meta-analysis showed that the use of ACEis/ARBs in patients with post-AKI is associated with a significantly lower risk of death (HR 0.80; 95% CIs, 0.72-0.90) and subgroup analysis showed a significant result in ACEi/ARB users with over 1-year of follow-up (HR 0.86; 95% CIs, 0.77-0.95).

Conclusions: The use of ACEi/ARB in patients with post-AKI is associated with a significantly lower risk of death.

Publication types

Meta-Analysis
Systematic Review

MeSH terms

Acute Kidney Injury / drug therapy*
Angiotensin Receptor Antagonists / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Databases, Factual
Humans

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors